Cellectar Biosciences Inc (NASDAQ:CLRB) shares, rose in value on Thursday, April 16, with the stock price up by 5.58% to the previous day’s close as strong demand from buyers drove the stock to $0.30.
Actively observing the price movement in the last trading, the stock closed the session at $0.28, falling within a range of $0.2801 and $0.299. The value of beta (5-year monthly) was 0.668. Referring to stock’s 52-week performance, its high was $3.51, and the low was $0.22. On the whole, CLRB has fluctuated by -22.48% over the past month.
With the market capitalization of Cellectar Biosciences Inc currently standing at about $13.78 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-12.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CLRB’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CLRB currently trading nearly -2.40% and -3.04% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 49.27, while the 7-day volatility ratio is showing 6.72% which for the 30-day chart, stands at 10.47%. Furthermore, Cellectar Biosciences Inc (CLRB)’s beta value is 0.48, and its average true range (ATR) is 0.03.
A comparison of Cellectar Biosciences Inc (CLRB) with its peers suggests the former has fared considerably weaker in the market. CLRB showed an intraday change of 5.58% in last session, and over the past year, it shrunk by -90.97%%.
Data on historical trading for Cellectar Biosciences Inc (NASDAQ:CLRB) indicates that the trading volumes over the past 10 days have averaged 0.67 and over the past 3 months, they’ve averaged 1.18 million. According to company’s latest data on outstanding shares, there are 46.08 million shares outstanding.
Nearly 1.67% of Cellectar Biosciences Inc’s shares belong to company insiders and institutional investors own 11.18% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.22 million shares as on 2025-03-31, resulting in a short ratio of 1.54. According to the data, the short interest in Cellectar Biosciences Inc (CLRB) stood at 532.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 1.97 million. This could raise investors’ confidence to be optimistic about the CLRB stock heading into the next quarter.
